IsoPlexis recently announced a partnership with the Institute for Systems Biology (ISB) to accelerate the development of improved detection methods that inform understanding and treatment of COVID-19. Uncovering functional immune responses using IsoPlexis’ technologies have underpinned key breakthroughs in therapies that harness the immune system across disease areas. To help accelerate vaccine development, the data from this partnership will be released as soon as possible and made globally available to researchers combating the disease.
This partnership will help map functional immune responses at the single cell level to study COVID-19 by looking at the immune response in patients who have been diagnosed or recovered from COVID-19, to learn more about contributing factors to outcome. Single cell functional proteomics and small sample CodePlex proteomic assays are being used to accelerate the fight against COVID-19 by helping uncover differences in response to and toxicity from COVID-19.
“Critical information from all aspects of the immune response will be key in understanding how to fight the disease and address complications.”
– James Heath
“Global effort and partnerships are needed to reach an accelerated understanding of COVID-19,” said James Heath, President of the Institute for Systems Biology. “Critical information from all aspects of the immune response will be key in understanding how to fight the disease and address complications. Functional phenotyping of each immune cell, using IsoPlexis’ system, will be a cornerstone of the understanding of this immune response in affected patients.”
“This partnership with the ISB underpins our goal to accelerate immune understanding and medicine in COVID-19. Through our unique functional analysis of each cell, we can unlock further understanding of how COVID-19 interacts with the immune system,” said Sean Mackay, CEO and co-founder of IsoPlexis. “Cellular immune signatures based on cytokines may be key in understanding and predicting response, and also how to mitigate disease progression.”
IsoPlexis’ IsoLight platform has the ability to measure 30+ proteins across thousands of single cells in parallel and researchers have already used the technology to look at cytokine production from immune cells in relation to next generation immune medicines. The goal is to analyze the cytokine profiles of immune cells from COVID-19 patients (both diagnosed and recovered). “Our objectives are two-fold. First, we want to understand which patients are at the highest risk of severe infection, so that critical medical resources can be most effectively utilized. Second, we will develop an in-depth understanding of what constitutes an effective immune response to the virus, so as to design better vaccines or therapies,” said Heath. IsoPlexis’ immune monitoring has been used in biomarker studies to predict patient responders and non-responders to therapies, and this technology may help to identify factors contributing to the success or failure of a potential vaccine.
“The collaboration is about applying our functional phenotyping technology to uncover these immune responses in a variety of patient samples… to, one, uncover the sources of immune response to the virus and, two, also help develop a better understanding therapeutically of what is going to work against the [virus],” Mackay said.
Dr. David Ho, a key member of IsoPlexis’ Scientific Advisory Board, is making a deep impact in the fight against COVID-19, detailed in his recent article on the cover of Bloomberg Businessweek for his quest for a treatment here: “Famed AIDS Researcher is Racing to Find a Coronavirus Treatment: Columbia’s David Ho is leading a group that’s trying to compress a five-year process into one.”
Combating Cytokine Storm in COVID-19 Patients
With various published datasets, it’s now been demonstrated that cytokine storm is a challenge with COVID-19. Patients who have severe complications to COVID-19 may be experiencing cytokine storm, a reaction where there is an overactive immune response that can lead to serious illness or sometimes death. So, IsoPlexis and ISB are working together to run highly multiplexed bulk analyses on
patient serum samples with the newly released CodePlex Secretome solution, in hopes of learning more about which patient populations may be more vulnerable to a cytokine storm. These efforts leverage years of single cell proteomic research into responses to pathogens and a range of immune mediated diseases.
IsoPlexis’ single cell functional proteomic data of T cells and myeloid cells are providing insights into differences in response. CodePlex has been used to accelerate insights from infectious disease vaccine development to next-generation immune medicines. These same mechanisms and cytokines are critical in COVID-19 related cytokine storm. The following list of cytokines, detectable with the Codeplex secretome panel, can help uncover mechanisms in severe toxicity: IL-1b, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-17, IL-10, MCP-1, GM-CSF, MIP-1a, MIP-1b, TNF-a, IFN-y, and more.
If you would like to discuss how IsoPlexis’ proteomics hub can accelerate your research speak to an expert here.